Table 3.
Univariate and multivariate analyses of overall survival.
| Characteristic | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| N (%) | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Age, years | < 75 | 569 (78.2) | ||||
| ≥ 75 | 159 (21.8) | 1.65 (1.26–2.17) | < 0.001 | 1.79 (1.28–2.51) | 0.001 | |
| CCI | < 3 | 620 (85.2) | ||||
| ≥ 3 | 108 (14.8) | 2.55 (1.92–3.39) | < 0.001 | 2.89 (1.96–4.27) | < 0.001 | |
| ECOG PS | 0 | 144 (19.8) | ||||
| 1–2 | 510 (70.1) | 2.16 (1.44–3.23) | < 0.001 | 2.08 (1.19–3.64) | 0.010 | |
| ≥ 3 | 74 (10.2) | 3.72 (2.25–6.14) | < 0.001 | 3.18 (1.62–6.25) | 0.001 | |
| Cytogenetics | Favorable | 254 (65.0) | ||||
| Unfavorable | 137 (35.0) | 1.24 (0.90–1.72) | < 0.001 | |||
| β2MG, mg/L | < 5.5 | 404 (57.8) | ||||
| ≥ 5.5 | 295 (42.2) | 1.86 (1.45–2.39) | < 0.001 | 1.65 (1.15–2.37) | 0.006 | |
| LDH | Normal | 440 (74.8) | ||||
| Abnormal | 148 (25.2) | 1.82 (1.36–2.43) | < 0.001 | 1.52 (1.06–2.19) | 0.024 | |
| R-ISS | Stage I | 40 (7.4) | ||||
| Stage II | 306 (56.4) | 1.50 (0.76–3.00) | 0.246 | 0.90 (0.44–1.83) | 0.769 | |
| Stage III | 197 (36.3) | 2.83 (1.42–5.63) | < 0.001 | 1.09 (0.49–2.42) | 0.836 | |
OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; CCI, Charlson comorbidity index; ECOG PS, Eastern Cooperative Oncology Group performance status; β2MG, β2 microglobulin; LDH, lactate dehydrogenase; R-ISS, revised international staging system.